Inozyme Pharma Announces Presentation Of Interim Data From Phase 1 SEAPORT 1 Trial At The Upcoming American Society Of Nephrology Kidney Week 2024
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma will present interim data from its Phase 1 SEAPORT 1 trial of INZ-701 for end-stage kidney disease at the ASN Kidney Week 2024.

October 17, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma is set to present interim data from its Phase 1 SEAPORT 1 trial at the ASN Kidney Week 2024, which could influence investor sentiment and stock price.
The presentation of interim data at a major conference like ASN Kidney Week can generate interest and potentially positive sentiment among investors, especially if the data is promising. This could lead to a short-term increase in INZY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90